Moreover, we definitively demonstrated that AKT activator (SC79) or JNK inhibitor (SP600125) could reverse the anticancer effects of rhoifolin on pancreatic cancer cells, including enhancement of antioxidant capacity, inhibition of proliferation, migration and invasion, and induction of apoptosis. This evidence concerns the gene AKT1 and pancreatic neoplasm.